Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing
Adalimumab but neither etanercept nor certolizumab-pegol has been reported to induce a wound-healing profile in vitro by regulating macrophage differentiation and matrix metalloproteinase expression, which may underlie the differences in efficacy between various TNF-α inhibitors in impaired wound he...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | JID Innovations |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667026723000760 |
| _version_ | 1797347750541524992 |
|---|---|
| author | Yonghao Cao Bohdan P. Harvey Liang Jin Susan Westmoreland Jing Wang Munish Puri Yingli Yang Holly M. Robb Sultan Tanriverdi Chenqi Hu Xue Wang Xiaofeng Xin Yingchun Liu Michael P. Macoritto Kathleen M. Smith Yu Tian Kevin White Timothy R.D.J. Radstake Zehra Kaymakcalan |
| author_facet | Yonghao Cao Bohdan P. Harvey Liang Jin Susan Westmoreland Jing Wang Munish Puri Yingli Yang Holly M. Robb Sultan Tanriverdi Chenqi Hu Xue Wang Xiaofeng Xin Yingchun Liu Michael P. Macoritto Kathleen M. Smith Yu Tian Kevin White Timothy R.D.J. Radstake Zehra Kaymakcalan |
| author_sort | Yonghao Cao |
| collection | DOAJ |
| description | Adalimumab but neither etanercept nor certolizumab-pegol has been reported to induce a wound-healing profile in vitro by regulating macrophage differentiation and matrix metalloproteinase expression, which may underlie the differences in efficacy between various TNF-α inhibitors in impaired wound healing in patients with hidradenitis suppurativa, a chronic inflammatory skin disease. To examine and compare the efficacy of various TNF inhibitors in cutaneous wound healing in vivo, a human TNF knock-in Leprdb/db mouse model was established to model the impaired cutaneous wound healing as seen in hidradenitis suppurativa. The vehicle group exhibited severe impairments in cutaneous wound healing. In contrast, adalimumab significantly accelerated healing, confirmed by both histologic assessment and a unique healing transcriptional profile. Moreover, adalimumab and infliximab showed similar levels of efficacy, but golimumab was less effective, along with etanercept and certolizumab-pegol. In line with histologic assessments, proteomics analyses from healing wounds exposed to various TNF inhibitors revealed distinct and differential wound-healing signatures that may underlie the differential efficacy of these inhibitors in accelerating cutaneous wound healing. Taken together, these data revealed that TNF inhibitors exhibited differential levels of efficacy in accelerating cutaneous wound healing in the impaired wound-healing model in vivo. |
| first_indexed | 2024-03-08T11:53:16Z |
| format | Article |
| id | doaj.art-655145936f1542ad926ac42c32f1ff28 |
| institution | Directory Open Access Journal |
| issn | 2667-0267 |
| language | English |
| last_indexed | 2024-03-08T11:53:16Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JID Innovations |
| spelling | doaj.art-655145936f1542ad926ac42c32f1ff282024-01-24T05:22:18ZengElsevierJID Innovations2667-02672024-01-0141100250Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound HealingYonghao Cao0Bohdan P. Harvey1Liang Jin2Susan Westmoreland3Jing Wang4Munish Puri5Yingli Yang6Holly M. Robb7Sultan Tanriverdi8Chenqi Hu9Xue Wang10Xiaofeng Xin11Yingchun Liu12Michael P. Macoritto13Kathleen M. Smith14Yu Tian15Kevin White16Timothy R.D.J. Radstake17Zehra Kaymakcalan18Transformational and Translational Immunology Discovery, AbbVie Bioresearch Center, Worcester, Massachusetts, USA; Correspondence: Yonghao Cao, Transformational and Translational Immunology Discovery, AbbVie Bioresearch Center, 100 Research Drive, Worcester, Massachusetts 01605, USA.Transformational and Translational Immunology Discovery, AbbVie Bioresearch Center, Worcester, Massachusetts, USADMPK-BA, AbbVie Bioresearch Center, Worcester, Massachusetts, USAPhamacology and Pathology, AbbVie Bioresearch Center, Worcester, Massachusetts, USAImmunology Computational Biology, AbbVie Cambridge Research Center, Cambridge, Massachusetts, USAPhamacology and Pathology, AbbVie Bioresearch Center, Worcester, Massachusetts, USAPhamacology and Pathology, AbbVie Bioresearch Center, Worcester, Massachusetts, USADiscovery Research, AbbVie, North Chicago, Illinois, USATransformational and Translational Immunology Discovery, AbbVie Bioresearch Center, Worcester, Massachusetts, USADMPK-BA, AbbVie Bioresearch Center, Worcester, Massachusetts, USADMPK-BA, AbbVie Bioresearch Center, Worcester, Massachusetts, USATransformational and Translational Immunology Discovery, AbbVie Bioresearch Center, Worcester, Massachusetts, USA; DMPK-BA, AbbVie Bioresearch Center, Worcester, Massachusetts, USA; Phamacology and Pathology, AbbVie Bioresearch Center, Worcester, Massachusetts, USA; Immunology Computational Biology, AbbVie Cambridge Research Center, Cambridge, Massachusetts, USA; Discovery Research, AbbVie, North Chicago, Illinois, USA; Global Biologics, AbbVie Bioresearch Center, Worcester, Massachusetts, USAImmunology Computational Biology, AbbVie Cambridge Research Center, Cambridge, Massachusetts, USAImmunology Computational Biology, AbbVie Cambridge Research Center, Cambridge, Massachusetts, USAImmunology Computational Biology, AbbVie Cambridge Research Center, Cambridge, Massachusetts, USADMPK-BA, AbbVie Bioresearch Center, Worcester, Massachusetts, USATransformational and Translational Immunology Discovery, AbbVie Bioresearch Center, Worcester, Massachusetts, USATransformational and Translational Immunology Discovery, AbbVie Bioresearch Center, Worcester, Massachusetts, USATransformational and Translational Immunology Discovery, AbbVie Bioresearch Center, Worcester, Massachusetts, USAAdalimumab but neither etanercept nor certolizumab-pegol has been reported to induce a wound-healing profile in vitro by regulating macrophage differentiation and matrix metalloproteinase expression, which may underlie the differences in efficacy between various TNF-α inhibitors in impaired wound healing in patients with hidradenitis suppurativa, a chronic inflammatory skin disease. To examine and compare the efficacy of various TNF inhibitors in cutaneous wound healing in vivo, a human TNF knock-in Leprdb/db mouse model was established to model the impaired cutaneous wound healing as seen in hidradenitis suppurativa. The vehicle group exhibited severe impairments in cutaneous wound healing. In contrast, adalimumab significantly accelerated healing, confirmed by both histologic assessment and a unique healing transcriptional profile. Moreover, adalimumab and infliximab showed similar levels of efficacy, but golimumab was less effective, along with etanercept and certolizumab-pegol. In line with histologic assessments, proteomics analyses from healing wounds exposed to various TNF inhibitors revealed distinct and differential wound-healing signatures that may underlie the differential efficacy of these inhibitors in accelerating cutaneous wound healing. Taken together, these data revealed that TNF inhibitors exhibited differential levels of efficacy in accelerating cutaneous wound healing in the impaired wound-healing model in vivo.http://www.sciencedirect.com/science/article/pii/S2667026723000760Hidradenitis suppurativaTNF inhibitorsWound healing |
| spellingShingle | Yonghao Cao Bohdan P. Harvey Liang Jin Susan Westmoreland Jing Wang Munish Puri Yingli Yang Holly M. Robb Sultan Tanriverdi Chenqi Hu Xue Wang Xiaofeng Xin Yingchun Liu Michael P. Macoritto Kathleen M. Smith Yu Tian Kevin White Timothy R.D.J. Radstake Zehra Kaymakcalan Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing JID Innovations Hidradenitis suppurativa TNF inhibitors Wound healing |
| title | Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing |
| title_full | Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing |
| title_fullStr | Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing |
| title_full_unstemmed | Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing |
| title_short | Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing |
| title_sort | therapeutic tnf inhibitors exhibit differential levels of efficacy in accelerating cutaneous wound healing |
| topic | Hidradenitis suppurativa TNF inhibitors Wound healing |
| url | http://www.sciencedirect.com/science/article/pii/S2667026723000760 |
| work_keys_str_mv | AT yonghaocao therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT bohdanpharvey therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT liangjin therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT susanwestmoreland therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT jingwang therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT munishpuri therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT yingliyang therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT hollymrobb therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT sultantanriverdi therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT chenqihu therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT xuewang therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT xiaofengxin therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT yingchunliu therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT michaelpmacoritto therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT kathleenmsmith therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT yutian therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT kevinwhite therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT timothyrdjradstake therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing AT zehrakaymakcalan therapeutictnfinhibitorsexhibitdifferentiallevelsofefficacyinacceleratingcutaneouswoundhealing |